To improve the lives of patients by creating & developing innovative antibody products

Genmab

Foundational Products:
Solid Financial Base, Significant potential

DARZALEX® (daratumumab), Arzerra® (ofatumumab), ofatumumab [RMS]

Our Own Clinical Pipeline
Potential first-in-class / Best-in-class

Tisotumab vedotin[1], enapotamab vedotin, HexaBody®-DR5/DR5, DuoBody®-CD3xCD20, DuoBody-PD-L1x4-1BB[2]

CTA Submitted: DuoBody-CD40x4-1BB[2]
2019 Projected IND/CTA: DuoHexaBody®-CD37

Partner Programs:
Additional Shots on Goal

10 in clinical development with partners; royalty streams for Genmab should they come to market. Includes 6 DuoBody products with Janssen

Technologies & Pre-Clinical
R&D Engine: Powerhouse of Innovation

DuoBody, HexaBody, DuoHexaBody, HexElect® platforms & rich-pre-clinical pipeline

Our Three-pronged Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable & successful biotech

Our Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Proprietary technologies allow us to build a world-class pipeline

Match in-house expertise with strategic partnerships

Strong pipeline of first-in-class / best-in-class products

Deep insight into antibody biology & disease targets

2019 Guidance

Income Statement	DKKM	USDM[3]
Revenue	4,800	738
Operating expenses	(2,750)	(423)
Operating income	2,050	315

[3]USD 1.00 = DKK 6.50

DKK
66B
~USD 10B[4]
2018 year end
Market cap

DKK
1,645M
~USD 248M[4]
2018 operating expenses
87% invested in R&D

[4]USD 1.00 = DKK 6.6446

DKK
3,025M
~USD 455M[4]
2018 revenue
28% increase vs 2017

DKK
6,106M
~USD 919M[4]
2018 year end cash position

Revenue
MDDK
(~MUSD[4])



For more information/contact: genmab.com/ir@genmab.com

[1]In collaboration with Seattle Genetics [2]In collaboration with BioNTech.
This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's final prospectus for our U.S. public offering and listing and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Aug 14, 2019

Innovation Powerhouse

Genmab Proprietary* Products and innovative Pre-clinical Pipeline

Product	Disease Indications	Most Advanced Dev. Phase
		Pre-clin. / I / I/II / II / III / Launch
Tisotumab vedotin Target: TF / Partner: Seattle Genetics	Cervical cancer	I/II
	Ovarian cancer	I/II
	Solid tumors	I/II
Enapotamab vedotin Target: AXL	Solid tumors	I/II
HexaBody-DR5/DR5 Target: DR5	Solid tumors	I
DuoBody-CD3xCD20 Targets: CD3, CD20	Hematological malignancies	I
DuoBody-PD-L1x4-1BB Targets: PD-L1, 4-1BB / Partner: BioNTech	Solid tumors	I
DuoBody-CD40x4-1BB Targets: CD40, 4-1BB / Partner: BioNTech	Solid tumors	Pre-clin.
IND / CTA expected in 2019	DuoHexaBody-CD37	Pre-clin.

* Certain products in co-development, partners as noted.

Marketed Products

Daratumumab Target: CD38 / Partner: Janssen	MM[5]	III / Launch
	AL Amyloidosis	II / III
	Non-MM blood cancers	II
Ofatumumab Target: CD20 / Partner Novartis	CLL[5,6]	III / Launch
	RMS	II / III

Partner Programs

Teprotumumab	Thyroid eye disease	II / III
HuMax-IL8 Target: IL8 / Partner: BMS	Advanced cancers	I/II
Camidanlumab tesirine Target: CD25 / Partner: ADCT	Lymphoma	I
	Advanced cancers	I
JNJ-61186372 Targets: EGFR, cMet /Partner: Janssen	NSCLC	I
JNJ-63709178 Targets: CD123, CD3 /Partner: Janssen	Acute Myeloid Leukemia (AML)	I
JNJ-64007957 Targets: BCMA, CD3 /Partner: Janssen	Relapsed or refractory MM	I
JNJ-64407564 Targets: GPRC5D, CD3 /Partner: Janssen	Relapsed or refractory MM	I
JNJ-67571244 Targets: CD33, CD3 /Partner: Janssen	AML	I
JNJ-63898081 Targets: PSMA, CD3 / Partner: Janssen	Solid tumors	I
Lu AF82422 Target: alfa-Synuclein/ Partner: Lundbeck	Parkinson's disease	I
Partnered programs	HuMab & DuoBody	Pre-clin.

Products & Technologies

Tisotumab vedotin
- Antibody-drug conjugate (ADC) in dev.
- to treat solid tumors
- Ph. II potential reg. study in cervical cancer
- Ph II studies in ovarian & other solid tumors
- 50:50 agreement w/ Seattle Genetics

Enapotamab vedotin
- ADC in development to treat solid tumors
- Ph I/II clinical study for multiple solid tumors

HexaBody-DR5/DR5
- Proprietary antibody therapeutic created w/ Genmab's HexaBody technology
- Phase I/II clinical trial in solid tumors

DuoBody-CD3xCD20
- Proprietary bispecific antibody created w/ Genmab's DuoBody technology
- Phase I/II clinical trial in B-cell malignancies

DuoBody-PD-L1x4-1BB
- Bispecific antibody created w/ DuoBody tech
- Phase I/II clinical trial in solid tumors announced
- 50:50 agreement w/ BioNTech

DuoBody-CD40x4-1BB
- Bispecific antibody created w/ DuoBody tech
- First CTA filed in March 2019
- 50:50 agreement w/ BioNTech

DARZALEX (daratumumab)
- First-in-class CD38 antibody
- Approved in certain territories for various multiple myeloma (MM) indications[5]
- Multiple Ph III studies ongoing in MM, amyloidosis & SubQ formulation
- Collaboration w/ Janssen
- 2018 net sales by Janssen: $2,025M

Arzerra (ofatumumab)
- Human CD20 monoclonal antibody developed in collaboration w/ Novartis
- Approved in certain territories for various chronic lymphocytic leukemia (CLL) indications[5,6]
- 2018 net sales by Novartis: $26M

Ofatumumab (OMB157)
- SubQ formulation in development to treat relapsing multiple sclerosis (RMS)
- Recruitment completed in 2 Ph. III studies in RMS

DuoBody Platform
- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

HexaBody Platform
- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform
- Antibody technology that combines
- DuoBody & HexaBody platforms
- Creates bispecific antibodies w/ target-mediated enhanced potency

HexElect Platform
- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting w/ enhanced selectivity & potency

Founded: 1999
Exchanges: CSE / Nasdaq
Symbol: GMAB
Shares outstanding: 64,967,643
Market Cap as of Aug. 14, 2019: DKK 84.8B (USD 12,721M)

Executive Management:
Jan G. J. van de Winkel, Ph.D. President & CEO
David A. Eatwell, FCCA, EVP & CFO
Judith Klimovsky M.D., EVP & CDO

[5] See local country prescribing information for precise indications
[6] Jan. 22, 2018: Novartis announced intention to transition Arzerra from commercially available to limited availability via compassionate use programs in non-US markets.